Menashe Benjamin, PhD

[email protected]

The Case for Reconstructed PACS: It's the functionality that matters

The concept of "deconstructed PACS" has generated much interest and controversy, but does it make the most sense for healthcare institutions? In a counterpoint to the deconstructed PACS argument, Menashe Benjamin, PhD, of Carestream Health claims that a single-vendor approach -- reconstructed PACS -- can better serve customers, yielding an enterprise imaging platform without the headaches of a deconstructed PACS model.

January 27, 2016

2016 01 27 15 42 41 618 Benjamin Menashe 200

Page 1 of 1

Astro 2026 Thumb 2

ASTRO: fractionated radiosurgery lessens brain metastases recurrence

Focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced recurrence risk.

ASTRO: Navigator program improves access for African American breast cancer patients

Knee Joint Pain 400

ASTRO: Low-dose RT tied to fewer knee replacements

Astro1

ASTRO: Ultra-low-dose RT controls myeloma bone pain

Free webinar for radiology leaders

Free webinar for radiology leaders

ASTRO: fractionated radiosurgery lessens brain metastases recurrence

By Amerigo Allegretto

Focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced recurrence risk.

September 28, 2026

Astro 2026 Thumb 2

ASTRO: Navigator program improves access for African American breast cancer patients

Afua Ofori-Darko, a medical student at Case Western Reserve, presented early phase I results of a structured patient navigation program.

September 28, 2026

ASTRO: Low-dose RT tied to fewer knee replacements

By Amerigo Allegretto

Patients who underwent low-dose RT had longer symptom relief, less joint deterioration, and lower disability risk.

September 27, 2026

Knee Joint Pain 400

ASTRO: Ultra-low-dose RT controls myeloma bone pain

The pain response rate was 59% at four weeks.

September 27, 2026

ASTRO: Limb-sparing care now standard for extremity sarcoma

In the 1970s, over 50% of extremity soft tissue sarcomas were treated by amputation.

September 27, 2026

Thomas DeLaney, MD, delivered a talk at ASTRO September 27 on preserving limbs in patients with extremity sarcoma.

ASTRO: Siemens unveils Accela radiotherapy system

By AuntMinnie.com staff writers

NeoArc allows stereotactic treatment to be delivered within a single breath hold.

September 27, 2026

Siemens Healthineers' Accela radiotherapy system

ASTRO: Proton RT controls high-risk neuroblastoma

Findings support PRT as a strategy to reduce long-term morbidity without compromising oncologic outcomes.

September 26, 2026

Astro 2026 Thumb 2

ASTRO: How does tumor location affect survival in patients with esophageal cancer?

Upper esophageal tumors were associated with the best survival, while middle esophageal location carried significantly worse odds.

September 26, 2026

Astro 2026 Thumb

CT-based AI model predicts pneumonitis in lung cancer patients

By Amerigo Allegretto

The algorithm outperformed clinical and radiomics models in these patients.

September 25, 2026

CIPHER, an AI-powered CT foundation model, identifies patients with lung cancer at increased risk of immunotherapy-induced pneumonitis before treatment begins. The AI-generated output, shown here, highlights lung abnormalities to support early risk assessment and personalized patient care.

Women's Imaging MinnieCast, Episode 18: On the road with the LBCA

By Amerigo Allegretto

The Lobular Breast Cancer Alliance (LBCA) is embarking on a nationwide bus tour to raise disease awareness.

September 25, 2026

Minnie Cast Thumbnail (26)

What are the effects of COVID-19 pneumonia after 5 years?

After five years, residual lesions persisted in 35.6% of survivors (37 of 104).

September 24, 2026

Representative longitudinal chest CT images and five-year parametric response mapping (PRM), pulmonary vascular CT reconstructions, and hyperpolarized xenon-129 (Xe-129) ventilation MRI scans from survivors of nonsevere and severe COVID-19 pneumonia. (A–F) Images in a 68-year-old male survivor of nonsevere COVID-19 pneumonia, (G–L) 62-year-old male survivor of severe COVID-19 pneumonia, and (M–R) 55-year-old male survivor of severe COVID-19 pneumonia. For each participant, the first three columns show coronal chest CT images from the acute phase (A, G, M), two-year follow-up (B, H, N), and five-year follow-up (C, I, O) (left to right). The fourth column (D, J, P) shows a coronal PRM image for each participant at five-year follow-up derived from paired inspiratory and expiratory CT scans, showing the spatial distribution of lung functional categories. Green indicates normal lung tissue, yellow indicates functional small airway disease, and red indicates emphysema. The second-to-last column shows volume-rendered small pulmonary vessel visualization (red) at five-year follow-up per participant (E, K, Q). The column on the far right (F, L, R) shows a hyperpolarized Xe-129 MRI ventilation defect percentage (VDP) map at five-year follow-up per participant. Dark blue represents high Xe-129 signal intensity, corresponding to well-ventilated lung regions, whereas red represents no Xe-129 signal intensity, corresponding to ventilation defects. At five-year follow-up, the 68-year-old survivor of nonsevere COVID-19 pneumonia (top row) showed near-complete radiologic resolution, no respiratory symptoms, and preserved pulmonary function. In contrast, the 62-year-old survivor of severe COVID-19 pneumonia (middle row) showed persistent fibrotic linear opacities without respiratory symptoms and mildly reduced pulmonary function. The 55-year-old survivor of severe COVID-19 pneumonia (bottom row) showed persistent scattered fibrotic linear opacities and focal emphysematous changes in both lungs, with dyspnea and impaired gas exchange function. The VDP values obtained from F, L, and R were 7.7%, 7.1%, and 6.3%, respectively.

USC researchers develop “plug-and-play" platform for PET tracers

Preliminary work suggests the approach can generate tracers targeting fibroblast activation protein.

September 24, 2026

Nuclear Medicine

Page 1 of 252